Valuation: Orexo AB

Market Cap 174M 17.67M 15.83M 14.6M 13.22M 24.71M 1.68B 25.11M 69.51M 881M 66.32M 64.91M 2.79B P/E 2024
-2.97x
P/E 2025 1.63x
Enterprise Value -247M -25.02M -22.41M -20.68M -18.71M -34.99M -2.38B -35.55M -98.41M -1.25B -93.9M -91.9M -3.95B EV / Sales 2024
1.62x
EV / Sales 2025 23.8x
Free-Float
78.37%
Yield 2024 *
-
Yield 2025 -
1 day-2.55%
1 week-11.29%
Current month-66.61%
1 month-65.86%
3 months-68.00%
6 months-75.71%
Current year-84.73%
1 week 4.51
Extreme 4.51
5.44
1 month 4.51
Extreme 4.51
14.8
Current year 4.51
Extreme 4.51
36
1 year 4.51
Extreme 4.51
36
3 years 4.51
Extreme 4.51
43.4
5 years 4.51
Extreme 4.51
43.4
10 years 4.51
Extreme 4.51
87.9
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2013
Director of Finance/CFO 59 01/09/2022
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 64 01/01/2002
Director/Board Member 70 11/04/2019
Director/Board Member 62 01/04/2022
Date Insider Type Main position Quantity % Market Cap. Importance
4/9/25 Buy

Chief Executive Officer

6 0.0000%
4/9/25 Free

Chief Executive Officer

1,393 0.0040%
3/9/25 Free 149 0.0004% -
Change 5-day change 1-year change 3-year change Capi.($)
-2.55%-11.29%-83.88%-71.98% 17.57M
+6.15%+4.51%+67.86%+141.40% 1,148B
+1.42%+2.62%+47.17%+86.78% 652B
+1.27%+1.30%+28.31%+103.60% 505B
+0.73%+2.45%+54.26%+66.47% 384B
+4.38%-0.57%+69.10%+42.58% 348B
+2.38%+2.65%+34.31%+56.33% 294B
+2.26%+0.55%+3.92%+27.74% 264B
+1.95%+2.81%+57.60%+74.71% 244B
+2.64%+2.93%+36.53%+108.04% 197B
Average +2.06%+0.06%+31.52%+63.57% 403.72B
Weighted average by Cap. +3.13%+1.50%+49.61%+92.92%

Financials

2024 2025
Net sales 590M 59.85M 53.6M 49.45M 44.75M 83.68M 5.7B 85.04M 235M 2.98B 225M 220M 9.45B 26M 2.64M 2.36M 2.18M 1.97M 3.69M 251M 3.75M 10.37M 131M 9.9M 9.69M 416M
Net income -203M -20.59M -18.44M -17.02M -15.4M -28.79M -1.96B -29.26M -80.99M -1.03B -77.28M -75.63M -3.25B 639M 64.85M 58.08M 53.59M 48.49M 90.68M 6.18B 92.14M 255M 3.23B 243M 238M 10.24B
Net Debt 353M 35.78M 32.04M 29.56M 26.75M 50.03M 3.41B 50.83M 141M 1.78B 134M 131M 5.65B -421M -42.69M -38.24M -35.28M -31.93M -59.7M -4.07B -60.66M -168M -2.13B -160M -157M -6.74B
Projected Income Statement - Annual - Orexo AB
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
55
Date Price Change Volume
30/10/26 SEK 4.595 -2.55% 369,430
28/10/26 SEK 4.715 -3.38% 74,801
27/10/26 SEK 4.880 -4.50% 70,294
26/10/26 SEK 5.110 -1.92% 41,780
23/10/26 SEK 5.210 +0.58% 130,396
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Orexo AB

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Orexo AB